Immunogenicity studies of recombinant RBD SARS-CoV-2 as a COVID-19 vaccine candidate produced in Escherichia coli

Immunogenicity studies of recombinant RBD SARS-CoV-2 as a COVID-19 vaccine candidate produced in Escherichia coli

The severe acute respiratory syndrome coronavirus 2 -related global COVID-19 pandemic has been impacting millions of people since its outbreak in 2020. COVID-19 vaccination has proven highly efficient in reducing illness severity and preventing infection-related fatalities. The World Health Organiza...

Full description

Bibliographic Details
Main Authors: Intan Aghniya Safitri, Yovin Sugijo, Fernita Puspasari, Fifi Fitriyah Masduki, Ihsanawati, Ernawati Arifin Giri-Rachman, Aluicia Anita Artarini, Marselina Irasonia Tan, Dessy Natalia
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Vaccine: X
Subjects:
RBD
COVID-19
SARS-CoV-2
Vaccine candidate
Escherichia coli
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136224000160

Internet

http://www.sciencedirect.com/science/article/pii/S2590136224000160

Similar Items